PharmTech AI Pulse Check panelists explain why attribution, audit trails, and sign-off matter more than AI watermark detection for GxP quality teams.
|Webcasts|September 27, 2020
Layer by Layer: The Fundamentals of Multi-Layer Tableting
Author(s)JRS PHARMA
***Live: Tuesday, Oct. 27, 2020 *** Multi-layer tableting offers an inexpensive and straightforward solution for a variety of challenging formulations. Learn how multi-layer formulations compare to traditional methods, gain insight to the multi-layer tableting process, and crucial tips to formulating and manufacturing robust multi-layer tablets. ***On demand available after final airing until Oct. 27, 2021***
Register free:
Event Overview:
Multi-layer tableting offers an inexpensive and straightforward solution for a variety of challenging formulations. Enabling multi-phasic release systems, combinations of incompatible APIs, and gastro-retentive tablets, this under-utilized method provides efficiency and cost-savings compared to more popular complex processes.
This webcast will compare multi-layer formulation options to traditional methods, providing a step-by-step guide to the multi-layer tableting process, and offering crucial tips to formulating and manufacturing robust multi-layer tablets. Learn how tooling considerations, excipient selection, layer design, and tamping force adjustment can impact overall tablet robustness, as well as layer-to-layer adhesion.
Key Learning Objectives:
- Understand the basics of multi-layer tablet formulations and its drug delivery possibilities.
- Follow step-by-step through the multi-layer tableting process.
- Learn essential tips for creating robust multi-layer tablets, from tooling considerations, excipient selection, layer design, to tamping force adjustment.
Speaker: Anthony Carpanzano, Director of R&D, JRS PHARMA
Time and Date: Tuesday, Oct. 27, 2020 at 11am EDT| 8am PDT| 4pm BST| 5pm CEST
On demand available after final airing until Oct. 27, 2021
Sponsor: JRS PHARMA
Register free:
Related to this article
Ron Scarboro, Azurity Pharmaceuticals, explains how cross-functional development, disciplined reformulation, and post-approval metrics can help proven medicines work in everyday use.
The FDA approves oral pritelivir for drug-resistant herpes sores in immunocompromised patients; what it means for antiviral development and manufacturing.
This week, drug formulation and manufacturing experts showcased their knowledge, and companies exhibited their products, at CPHI Milan.
FDA approves Teva’s Weltruza, a once-monthly subcutaneous olanzapine for schizophrenia whose copolymer depot eliminates post-injection monitoring.
Equivalence test using two one-sided tests are widely used for demonstrating the comparability of treatment effects in different research fields. The method described in the manuscript aims to use simulations in Microsoft Excel to compute power for 2 one-sided tests for two groups with unequal variances.
Richard Jaenisch examines whether FDA's NAM pathway truly shortens drug pipelines or just shifts the evidentiary burden elsewhere.
Susan J. Schniepp, distinguished fellow with Nelson Labs, and Siegfried Schmitt, PhD, vice president, Technical, with Parexel, clear up some of the confusion about what does and does not need to be complied with regarding standards set by international pharmacopoeias.
Trending on Pharmaceutical Technology
1
CPHI Milan 2026: Nitrosamine Risk Mitigation, Part 2
2
Pritelivir Shifts Resistant Herpes Care from Intravenous to Oral
3
Symptomatic Dermographism: Novartis Lands Remibrutinib Label Expansion
4
PharmTech AI Pulse Check: Availability Bias Threatens AI Regulatory Reviews
5